REGENXBIO, Inc. (RGNX)

REGENXBIO's stock (RGNX) experienced a 51.69% increase over the past year as of April 9, 2026, but a year-to-date return of -40.76% as of April 3, 2026. The FDA placed a clinical hold on RGX-111 and RGX-121 in January 2026, causing the stock to fall approximately 18%. In March 2026, the company reported positive interim data from its RGX-202 trial and its fourth-quarter and full-year 2025 financial results.

There is no explicit mention or indication of demand seasonality for REGENXBIO's gene therapy products and services. Demand is likely driven by patient need and medical adoption rather than seasonal fluctuations. Stock performance might exhibit some seasonality.

REGENXBIO, Inc. is a clinical-stage biotechnology company focused on gene therapy, operating within the healthcare sector. It develops, commercializes, and licenses recombinant adeno-associated virus (AAV) gene therapy using its NAV Technology Platform. Key product candidates include ABBV-RGX-314 for retinal diseases, RGX-202 for Duchenne muscular dystrophy, RGX-121 for mucopolysaccharidosis type II (MPS II), RGX-111 for mucopolysaccharidosis type I (MPS I), and RGX-181 and RGX-381 as additional therapeutic programs.

REGENXBIO Inc. is headquartered in Rockville, Maryland, United States. Its gene therapies are provided in the United States, and it has collaboration and license agreements with partners like Nippon Shinyaku Co., Ltd. for development outside the United States.

REGENXBIO's brand reputation has been impacted by the FDA clinical hold on its RGX-111 and RGX-121 programs, leading to a securities class-action lawsuit. However, the company has also been recognized as a Top Workplace and continues to present positive data for other pipeline candidates like RGX-202.

REGENXBIO Inc. is primarily owned by institutional shareholders, who hold 79.71% of the stock, with insiders owning 24.95% and retail investors holding 0.00%. Major institutional owners include BlackRock, Inc., Redmile Group, LLC, and The Vanguard Group Inc. The largest individual shareholder is Allan M. Fox, owning 13.38% of the company.